-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On November 2, the official website of the State Food and Drug Administration showed that the zoledronic acid injection of Sichuan Hairong Pharmaceutical of Yangzijiang Pharmaceutical Group was approved as a supplementary application
November 02, 2021, the drug approval document pending information is released
Zoledronic acid is the third-generation bisphosphonate.
According to Meinenet data, in 2020, the sales of terminal zoledronic acid injection in China's urban public hospitals, county-level public hospitals, urban community centers, and township health centers (Chinese public medical institutions) exceeded 1 billion yuan, a year-on-year increase in the first half of this year.
It is worth noting that in recent years, with the efforts of domestic pharmaceutical companies, Novartis' market share has gradually declined, from nearly 70% in 2017 to less than 50% in 2020, and has fallen below 40% in the first half of this year
Yangtze River has reviewed injections since 2021
Source: Meinenet MED2.
Since the beginning of this year, Yangtze River has received 19 injections, covering multiple subcategories such as anti-tumor drugs, anesthetics, and contrast agents.
Source: official website of the State Food and Drug Administration, Mi Nei.
